Natus Medical (BABY) Stock Rating Lowered by BidaskClub
BidaskClub lowered shares of Natus Medical (NASDAQ:BABY) from a hold rating to a sell rating in a report published on Saturday morning.
Separately, Zacks Investment Research upgraded Natus Medical from a hold rating to a buy rating and set a $45.00 price target for the company in a research report on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $46.50.
Shares of Natus Medical (NASDAQ BABY) opened at $39.55 on Friday. The stock has a market capitalization of $1,171.40, a PE ratio of 24.26 and a beta of 0.84. The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36. Natus Medical has a 12-month low of $31.65 and a 12-month high of $43.60.
In related news, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares in the company, valued at approximately $6,068,074.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The disclosure for this sale can be found here. Insiders sold a total of 22,042 shares of company stock valued at $902,266 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in BABY. Benjamin F. Edwards & Company Inc. increased its stake in Natus Medical by 2,085.6% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 2,607 shares during the period. Riverhead Capital Management LLC increased its stake in Natus Medical by 90.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 1,364 shares during the period. Sei Investments Co. increased its stake in Natus Medical by 29.7% in the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after purchasing an additional 728 shares during the period. SG Americas Securities LLC purchased a new position in Natus Medical in the 3rd quarter worth approximately $138,000. Finally, Victory Capital Management Inc. increased its stake in Natus Medical by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after purchasing an additional 560 shares during the period. Institutional investors own 94.39% of the company’s stock.
WARNING: “Natus Medical (BABY) Stock Rating Lowered by BidaskClub” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/natus-medical-baby-stock-rating-lowered-by-bidaskclub/1760294.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.